Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
1-15 of 407
Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Project Oncology®Exploring Treatment Strategies in epNEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP
Jason Starr, DO
- NEW EPISODE
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
MinuteCE®From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
- NEW EPISODE
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
MinuteCE®ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- NEW EPISODE
Precision in Practice—Bringing Targeted Therapy to mHSPC
MinuteCE®Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- NEW EPISODE
The Power of Timing: Therapies That Change Outcomes
MinuteCE®The Power of Timing: Therapies That Change Outcomes
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- NEW EPISODE
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
MinuteCE®Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- advertisement
Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Project Oncology®Overcoming Clinical Inertia to Individualize Myelofibrosis Treatment
Alexandria May, PharmD, BCPS
Prithviraj Bose, MD
Applying Clinical Trial Data in mCSPC Care
Project Oncology®Applying Clinical Trial Data in mCSPC Care
Steve Jackson, PharmD
Jahan Aghalar, MD
Ulka Vaishampayan, MD
Personalizing Long-Term mCSPC Treatment Decisions
Project Oncology®Personalizing Long-Term mCSPC Treatment Decisions
Charles Turck, PharmD, BCPS, BCCCP
Bilal Siddiqui, MD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CEPrecision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
Interpreting and Applying cGVHD Clinical Trial Data
Project Oncology®Interpreting and Applying cGVHD Clinical Trial Data
Charles Turck, PharmD, BCPS, BCCCP
Christopher Graham, MD
Evidence-Based Treatment Decisions in Metastatic Triple-Negative Breast Cancer
Project Oncology®Evidence-Based Treatment Decisions in Metastatic Triple-Negative Breast Cancer
Alexandria May, PharmD, BCPS
Neil M. Iyengar, MD
- advertisement
MCED Testing for Breast Cancer: Opportunities and Limitations
On the Frontlines of Metastatic Breast CancerMCED Testing for Breast Cancer: Opportunities and Limitations
Alexandria May, PharmD, BCPS
Marie Wood, MD
Rethinking Frontline Care in HER2- Metastatic Breast Cancer
On the Frontlines of Metastatic Breast CancerRethinking Frontline Care in HER2- Metastatic Breast Cancer
Alexandria May, PharmD, BCPS
Tiffany Traina, MD
How Genetic Testing Guides Personalized mBC Care
On the Frontlines of Metastatic Breast CancerHow Genetic Testing Guides Personalized mBC Care
Alexandria May, PharmD, BCPS
Marie Wood, MD
